Abstract: Ligands for transition metals are disclosed herein, which may be used in various transition-metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The disclosed methods provide improvements in many features of the transition-metal-catalyzed reactions, including the range of suitable substrates, number of catalyst turnovers, reaction conditions, and efficiency. For example, improvements have been realized in transition-metal-catalyzed cross-coupling reactions.

Abstract: On producing a purified borazine compound, a borazine compound is filtrated under an atmospheric condition of a water content of not higher than 2000 volume ppm. Or, on filling a borazine compound into a container, the above described borazine compound is filled into the above described container under an atmospheric condition of a water content of not higher than 2000 volume ppm. Or, as a container for preservation for preserving a borazine compound, a container for preserving a borazine compound, which has withstanding pressure of not lower than 0.1 MPa, is used.

Abstract: Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.

Abstract: The invention provides a synthetic and manufacturing process for the preparation of the anticancer drug, fluorapacin, bis(4-fluorobenzyl)trisulfide, and related trisulfide derivatives on large scale. Also provided are processes for the purification and isolation of fluorapacin having high purity and improved stability.

Abstract: Novel processes for preparing arylsulfur pentafluorides are disclosed. Processes include reacting at least one aryl sulfur compound with a halogen and a fluoro salt to form an arylsulfur halotetrafluoride. The arylsulfur halotetrafluoride is reacted with a fluoride source to form a target arylsulfur pentafluoride.

Abstract: Method of producing compounds of the general formula XPR2(OR1)??Ia where X is chlorine, bromine or iodine and R1 is an organic radical, by reacting compounds of the general formula X2PR2??II, in which X has the meaning given above and R2 is an organic radical, with compounds of the general formula R1OH??III, in which R1 has the meaning given above, to give a mixture IV, in that a) the postreaction is carried out at a temperature of from 50 to 240° C. and a pressure of from 0.001 to 0.9 bar, b) from the mixture IV the compounds Ia are separated off from the compounds PR2(OR1)2??Ib and, if appropriate, the compounds II and c) compounds Ib and, if appropriate, unreacted compounds II are returned to the synthesis stage.

Abstract: There are provided compositions comprising a first compound selected from the group consisting of compounds of formulas (Ib), (III), (V), and (VII), and a second compound selected from the group consisting of compounds of formulas (IIb), (IV), (VI), and (VIII): Various chemical entities can be used for R4 to R11. These compositions can be particularly useful as anti-static agents or as electron activable precursors to a redox couple.

Abstract: A method of synthesizing a heteroleptic, multiple metal-containing metallocyclic catalyst, particularly suited for asymmetric catalysis, comprising combining a plurality of plural functional group-containing, monodentate ligands of complementary chirality, said plural functional groups being tethered to each other by tethers in the presence of a scaffold-structural metal Ms or derivative thereof, wherein at least one functional group on each ligand combines to ligate Ms to form a bidentate, Ms centered ligand scaffold containing the remaining functional groups and combining said bidentate ligand scaffold with a catalytic metal Mc or derivative thereof whereby the remaining functional groups combine to ligate Mc, thereby forming said catalyst.

Abstract: Alkyl(methoxymethyl)trimethylsilanylmethylamines are prepared by reacting alkyltrimethylsilanylmethylamines with a substantially equimolar amount of paraformaldehyde and methanol in the presence of a base.

Abstract: Taught are pharmaceutical compositions comprising at least one phospholipid having at least one docosahexaenoyl (DHA) residue, such as a lecithin-DHA-type phospholipid, and methods for treating or preventing respiratory failure of a patient comprising administering these pharmaceutical compositions to a patient in need of such treatment or prevention.

Abstract: An organic semiconducting layer formulation containing an organic binder which has a permittivity, ?, at 1,000 Hz of 3.3 or less and a polyacene compound of Formula A: and processes for the preparation thereof and uses thereof in various electronic devices.

Abstract: A manufacturing method for one of, or a mixture of, an optically active allylboron compound and racemic or optically active boryl cyclopropane, including a coupling reaction, in the presence of a catalyst, between allyl compound and diboron compound. It is preferred that a copper (I) complex is used as the catalyst. It is preferred that a counterion of the copper (I) complex is an alkoxide or a hydride. It is preferred that the copper (I) complex has a phosphine ligand. It is preferred that the phosphine ligand is a chiral phosphine ligand.

Abstract: The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

Abstract: Method and system for forming an anhydrous sterilant. In one embodiment, anhydrous peracetic acid is combined with carbon dioxide, wherein the carbon dioxide is in one of a liquid, solid, and supercritical state.

Abstract: A method for producing a polymeric material comprises reacting a first reactant with a second reactant. The first reactant comprises anhydrous phosphorous pentoxide and the second reactant comprises an alcohol. A method for producing a polymeric salt material comprises reacting a first reactant comprising an amine with a second reactant comprising a phosphate ester.

Abstract: The present invention is directed to fluoro silicone acrylates that are used in reaction either alone or with other monomers to make polymers that can modify the surface of hair skin or pigment. This makes them ideal for incorporation into pigmented products in personal care applications like make up and lipsticks.

Abstract: A novel sulfonium borate complex, which can reduce the amount of fluorine ions produced during thermal cationic polymerization, and realize low-temperature, rapid curing properties in a thermal cationic polymerizable adhesive, is represented by the structure of the following formula (1). In the formula (1), R1 is an aralkyl group and R2 is a lower alkyl group. However, when R2 is a methyl group, R1 is not a benzyl group. X is a halogen atom, and n is an integer of 1 to 3.

Abstract: A primary phosphine or a secondary phosphine is reacted with an ester compound selected from the group consisting of; a phosphate triester; a phosphonate diester; a sulfate diester; and a sulfonate ester; to form a phosphonium salt of formula (VII) wherein each of RQ, RX, RY, and RZ is independently hydrocarbyl and X? is a phosphate, phosphonate, sulfate, or sulfonate. These phosphonium salts may find utility in a wide range of applications, including as surfactants, as polar solvents (ionic liquids), as antimicrobial agents, and as a component of spinning finish in polyamide fiber processing.

Abstract: A nanoparticle includes a chain oligomer section having a hydrophilic group and fluoroalkyl groups respectively at its opposite terminals, a three-dimensional silica network section, and an organic chain having fluorine or silicon, and is represented by the following formula (1): where R? is independent H or independent alkyl group; X is the hydrophilic group and is independent OH group, independent NCO group, independent NH2 group or the like; RF is the fluoroalkyl group having a carbon number of 2 to 10 and a molecular weight of 119 to 1000; 3D-SN is the three-dimensional silica network section; B is independent O, independent O?C—O or the like; E is O, O?C—O, NH—C?O or the like; G is [(CH2O)1—[Si(CH3)2O]k—(CH2O)1] or the like.

Abstract: This invention relates to polyoxometalates represented by the formula (An)m+[My(H2O)pXzZ2W18O66]m?1 or solvates thereof, wherein A represents a cation acting as counterion of the polyanion, n is the number of the cations A, m is the charge of the polyoxoanion, M represents a transition metal selected from Cu, Zn, Pd, Pt and mixtures thereof, y is the number of transition metals M and is a number from greater than 4 to less than 6, p is a number of water molecules and is a number from 0 to 10, X is a halide selected from F, Cl, Br, I and mixtures thereof, z is a number of halides and is a number from 0 to 6 and Z represents a heteroatom selected from SbIII, BiIII, AsIII, SeIV and TeIV.